secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2025-07-17T23:59:59+00:00
Accession:  0001641172-25-019976
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow secures exclusive U.S. rights to two ophthalmology biosimilars from Samsung Bioepis
--------------------------------------------------------------------------------

- Gains exclusive U.S. commercial rights to BYOOVIZ (ranibizumab-nuna) and OPUVIZ (aflibercept-yszy), FDA-approved biosimilars of Lucentis and Eylea.
- Consideration includes one-time upfront payment, net-sales milestone payments, and a share of U.S. net sales (amounts not disclosed).
- Transition of commercial rights from Biogen to Samsung expected by end of 2025; Harrow will then assume full commercialization.
- U.S. retinal disease treatment market valued at ~$9B; products target Wet AMD, Macular Edema, DME, and Diabetic Retinopathy.
- CEO Mark Baum calls the acquisition transformational, reinforcing Harrow's commitment to affordable alternatives in eyecare.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/0001641172-25-019976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000164117225019976/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-019976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer